All In Biotech

Drug Trial Radar · NCT07189455

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Dec 12, 2025

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Conditions

  • Small-cell Lung Cancer

Interventions

  • ZG006Drug

    ZG006 will be administered as an intravenous (IV) infusion.

  • TopotecanDrug

    Topotecan will be administered per local standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.